and current exercise price of $10.30 per share, subject to further adjustment pursuant to customary anti-dilution provisions, and the 154,376 Series B Warrants outstanding to purchase up to,
after giving effect to the reverse stock split on September 13, 2018, an aggregate of 7,719 shares of Common Stock at an initial and current exercise price of $12.88 per share, subject to further adjustment pursuant to customary anti-dilution
provisions. The Series A & B Warrants expire at the close of business on July 27, 2021. The Series A & B Warrants may only be exercised within 30 days of the Expiration Date. The shares to be issued under the Series
A & B Warrants represent less than 1% of the outstanding shares of our Common Stock as of May 24, 2019 on a fully diluted basis.
Series
C Warrants
On January 29, 2018, we entered into a warrant agreement (the Series C Warrant Agreement) with CST, as
warrant agent. Pursuant to the Series C Warrant Agreement, we issued 8,286,061 warrants (the Series C Warrants). As of May 24, 2019, there were 6,940,655 Series C Warrants outstanding. The Series C Warrants give the holder the right
to purchase up to, after giving effect to the reverse stock split on September 13, 2018, an aggregate of 347,033 shares of Common Stock at an initial exercise price of $0.0001 per share, subject to further adjustment pursuant to customary
anti-dilution provisions. The Series C Warrants may generally be exercised at any time and from time to time. The shares of Common Stock to be issued under the Series C Warrants represent 1.7% of the outstanding shares of our Common Stock as of
May 24, 2019 on a fully diluted basis.
Series D Warrants
On May 8, 2018, we entered into a warrant agreement (the Series D Warrant Agreement) with CST, as warrant agent. Pursuant to
the Series D Warrant Agreement, we issued 14,098,370 warrants (the Series D Warrants). As of May 24, 2019, there were 11,274,419 Series D Warrants outstanding, which give the holders the right to purchase up to, after giving effect
to the reverse stock split on September 13, 2018, an aggregate of 563,721 shares of the Common Stock at an initial exercise price of $0.0001 per share, subject to further adjustment pursuant to customary anti-dilution provisions. The Series D
Warrants may generally be exercised at any time and from time to time. The shares of Common Stock to be issued under the Series D Warrants represent 2.7% of the outstanding shares of our Common Stock as of May 24, 2019 on a fully diluted basis.
Series E Warrants
On
September 6, 2018, the Company entered into a warrant agreement (the Series E Warrant Agreement) with CST, as warrant agent. Pursuant to the Series E Warrant Agreement, we issued 94,813,594 warrants (the Series E
Warrants and, together with the Series A & B Warrants, the Series C Warrants, and the Series D Warrants, the Existing Warrants). As of May 24, 2019, there were 54,552,934 Series E Warrants outstanding, which give the
holder the right to purchase up to, after giving effect to the reverse stock split on September 13, 2018, an aggregate of 2,727,647 shares of Common Stock, subject to further adjustment pursuant to customary anti-dilution provisions, at an
exercise price of $0.0001 per share. The Series E Warrants may generally be exercised at any time and from time to time. The shares of Common Stock to be issued under the Series E Warrants represent 13.2% of the outstanding shares of our Common
Stock as of May 24, 2019 on a fully diluted basis.
Conversion Warrants
See the above description under Convertible Notes.
Dividends
We have not
paid any cash dividends on our Common Stock to date. It is the present intention of our board of directors to retain all earnings, if any, for use in our business operations and, accordingly, our board does not anticipate declaring any dividends in
the foreseeable future. The payment of dividends will be within the discretion of our board of directors and will be contingent upon our revenues and earnings, if any, capital requirements and general financial condition, and the restrictions on
dividends under our current financing arrangements
8